ClinicalTrials.gg
Not yet recruitingNCT07666594Updated Jun 24, 2026

Mobile App-Based Yoga and Meditation in Rheumatoid Arthritis

An interventional study of Mobile App-Based Yoga and Meditation in Rheumatoid Arthritis (RA), Anxiety and Depression Anxiety Disorder, sponsored by Tugba Civi Karaaslan. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Tugba Civi Karaaslan · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Arthritis, Rheumatoid with a site in Turkey — 14 open to participants now, 19 under way, 2 of them phase 3. Arthritis, Rheumatoid · Turkey.

Planned enrollment
31st of 78
102 · median 77
Started
2026
with 5 others
No phase
44 of 128
5 open now
Primary completion
2027-05
later than 15 of 18 live
Registered
121st of 128
by date

Among the 128 studies in Arthritis, Rheumatoid with a site in Turkey, this one is the 31st largest by planned enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2026, is one of 44 with no phase, reaches primary completion later than 15 of the 18 other live ones, and was the 121st registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

14 of the 128 studies in Arthritis, Rheumatoid with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Arthritis, Rheumatoid with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this single-blind, randomized controlled trial is to evaluate the clinical effectiveness and short-term economic impact of a mobile application-based, personalized yoga and meditation program in adult patients with Rheumatoid Arthritis (RA).

The main questions it aims to answer are:

Does an 8-week digital yoga and meditation intervention reduce anxiety and improve other clinical/psychological outcomes (such as depression, pulmonary function, reaction time, quality of life, and stress) compared to standard medical care? Does this digital intervention reduce short-term healthcare utilization and associated direct medical costs?

Researchers will compare the Mobile App Group (receiving personalized yoga and meditation via the Meditopia app) to a Control Group (receiving usual medical care) to evaluate the effectiveness and cost-efficiency of the intervention.

Participants in the experimental group will:

Use a mobile application to practice 15-30 minutes of yoga and 15-30 minutes of meditation daily, at least 4 days a week over an 8-week period.

Complete clinical, psychometric, and economic assessments at baseline, week 4, and week 8.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Anxiety
  • Depression Anxiety Disorder
  • Mobile Health Technology (mHealth)

Keywords

  • Rheumatoid Arthritis
  • Yoga
  • Mobile Health (mHealth)
  • Meditation
  • Cost Analysis
  • Psychological Stress
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged between 18 and 65 years.
  • Diagnosed with Rheumatoid Arthritis (RA) by a rheumatologist.
  • Disease in a stable phase (remission or low disease activity).
  • Access to a smartphone or tablet and sufficient proficiency in using mobile applications.
  • Cognitive sufficiency to provide written and verbal in Turkish.

Exclusion criteria

Exclusion Criteria:

  • Presence of acute RA flare-ups.
  • Severe psychiatric diagnoses (e.g., psychosis, bipolar disorder, or severe major depression).
  • Severe cognitive impairment or dementia.
  • Pregnancy.
  • Regular practice of meditation or mindfulness within the last 6 months.
  • Participation in any other stress management program within the last 3 months.
  • Receipt of mental health services within the last 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Mobile Application Group

    Participants in this group will receive a personalized 8-week yoga and meditation program via the Meditopia mobile application, in addition to their usual medical care.

    Behavioral: Mobile App-Based Yoga and Meditation

  • No intervention
    Control Group

    Participants in this group will continue their usual medical follow-up and routine care without any structured digital mind-body intervention.

Interventions

  • BehavioralMobile App-Based Yoga and Meditation

    The intervention consists of an 8-week individualized program. It includes yoga sequences selected by a physiotherapist based on the patient's functional capacity and joint mobility. It also includes mindfulness-based and emotion regulation-focused meditation content selected by a clinical psychologist. Participants are expected to practice for 15-30 minutes of yoga and 15-30 minutes of meditation daily, at least 4 days a week.The intervention is delivered through the Meditopia mobile application.

06

What researchers measure

Primary outcomes

  1. Hospital Anxiety and Depression Scale - Anxiety (HADS-A)

    Evaluated using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The HADS-A is a 7-item self-report scale scored from 0 to 21. Higher scores indicate a greater symptom burden of anxiety.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2).

Secondary outcomes

  1. Perceived Stress Scale (PSS-10)

    Measured by the Perceived Stress Scale (PSS-10), a 10-item tool (scored 0-40) assessing how unpredictable or uncontrollable patients find their lives.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  2. Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale (FSS) is a 9-item self-report scale used to evaluate the impact of fatigue on daily functioning and social life. Each item is scored on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated as the mean of the 9 items, with a final score ranging from 1 to 7. A higher mean score indicates a greater severity of fatigue and a more significant impact of fatigue on the individual's daily activities.

    Time frame: Baseline and Week 8

  3. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire used to assess sleep quality and disturbances over a one-month time interval. It evaluates seven 'component' scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored from 0 to 3, yielding a global score ranging from 0 to 21. A total global score of greater than 5 is generally used to indicate poor sleep quality. Higher global scores represent poorer sleep quality and more significant sleep disturbances.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  4. Rheumatoid Arthritis Quality of Life (RAQOL)

    The Rheumatoid Arthritis Quality of Life (RAQOL) questionnaire is a disease-specific instrument designed to assess the quality of life in patients with rheumatoid arthritis using a needs-based model. It consists of 30 items with a binary response format (Yes/No). Each 'Yes' response is scored as 1, and each 'No' response is scored as 0. The total score ranges from 0 to 30, with higher scores representing a poorer quality of life and a greater negative impact of the disease on the individual's life. The scale focuses on various domains, including mood, social life, hobbies, everyday tasks, and physical contact.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  5. Chronic Illness Self-Management (CISM) Scale

    The Chronic Illness Self-Management (CISM) scale is a 23-item tool designed to assess the self-management behaviors and perceptions of individuals living with chronic conditions. It consists of four subscales: Self-Stigma (7 items), Coping with Stigma (5 items), Healthcare Effectiveness (5 items), and Treatment Adherence (6 items). Each item is evaluated based on the patient's experience, providing a comprehensive measure of how well the individual manages the challenges associated with their illness. Higher scores in specific domains indicate better self-management capabilities and adaptation to the chronic condition.

    Time frame: Baseline (T0) and Week 8 (T2)

  6. Forced Vital Capacity (FVC)

    Quantitative measurement of respiratory function will be performed using a calibrated spirometer in accordance with the ATS/ERS standardization protocols. FVC (expressed in Liters) will be recorded in a seated position to assess the presence and severity of extra-articular pulmonary involvement. The best of at least three acceptable maneuvers will be used for analysis.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  7. Forced Expiratory Volume in 1 Second (FEV1)

    Quantitative measurement of respiratory function assessed using a calibrated spirometer in accordance with the ATS/ERS standardization protocols. FEV1 measures the volume of air exhaled in the first second of the forceful exhalation.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  8. FEV1/FVC Ratio

    The ratio of Forced Expiratory Volume in 1 second to Forced Vital Capacity, calculated from the spirometry maneuver to assess obstructive or restrictive pulmonary patterns.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  9. Peak Expiratory Flow (PEF)

    Quantitative measurement of respiratory function assessed using a calibrated spirometer in accordance with the ATS/ERS standardization protocols. PEF measures the maximum speed of expiration.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  10. Visual Reaction Time (BlazePod)

    Visual reaction time will be measured using the BlazePod device, a portable visual-cognitive technology designed to assess response speed to light stimuli. Simple and selective reaction time tasks will be performed where participants respond by touching or tapping the pod when it illuminates. To ensure reliability, each participant will complete multiple trials (typically 5-10), and the average reaction time in milliseconds will be calculated after excluding outliers. The testing procedure will be standardized regarding lighting conditions, distance, and participant positioning. This measurement serves as a neurocognitive performance indicator to evaluate the systemic and cognitive effects of the intervention.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2)

  11. Total Direct Healthcare Costs (Partial Cost Analysis)

    A partial cost analysis will be conducted from a healthcare system perspective to evaluate the short-term economic impact of the digital intervention. Data on healthcare resource utilization-including the number of planned or unplanned rheumatology/internal medicine outpatient visits, emergency room admissions, and the number and duration of hospitalizations-will be collected retrospectively for the 8-week period using a structured 'Healthcare Utilization Questionnaire'. To calculate the total direct medical cost per patient, these frequency data will be multiplied by official unit costs derived from the current Social Security Institution (SGK) Health Implementation Communiqué (SUT) tariffs and supported by relevant cost-of-illness literature in Turkey. This analysis aims to provide preliminary empirical evidence on the cost-effectiveness of integrating mobile mind-body interventions into the routine management of Rheumatoid Arthritis.

    Time frame: Baseline (T0) and Week 8 (T2)

  12. System Usability Scale (SUS)

    The System Usability Scale will be administered only to participants in the intervention group to evaluate the usability, ease of use, and overall acceptability of the digital system used during the intervention. The SUS is a validated 10-item questionnaire scored on a 5-point Likert scale. Total scores range from 0 to 100, with higher scores indicating better perceived usability and user satisfaction with the system.

    Time frame: At the end of the 8-week intervention

07

Study locations

1 site
  • Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology
    Istanbul, Istanbul 34500, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 11 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Jun 24, 2026
StartEst.
Jun 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07666594
Lead sponsor
Tugba Civi Karaaslan
Responsible party
Tugba Civi Karaaslan (Assistant Professor, Istanbul University) — Sponsor-investigator
First posted
Jun 24, 2026
Start date
Jun 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Tuğba Çivi Karaaslan, PhD
Contact
tugba.civi@iuc.edu.tr
+902124141500 ext. 40193
Pedram Shahriyari, PT
Contact
+905346838530

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion